



For **reauthorization**:

1. Hemgenix is a one-time single infusion and will not be reauthorized.

**CareSource considers Hemgenix (etranacogene dezaparvovec) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.**

| DATE       | ACTION/DESCRIPTION               |
|------------|----------------------------------|
| 01/13/2023 | New policy for Hemgenix created. |

References:

1. Hemgenix [prescribing information]. uniQure, Inc.; 2022.
2. Miesbach W, Leebeek F, Recht M, et al. Final analysis from the pivotal phase 3 HOPE-B gene therapy trial: Stable steady-state efficacy and safety of etranacogene dezaparvovec in adults with se518( )47(s49 rg 575.95 615.82 4